Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00376857
Recruitment Status : Completed
First Posted : September 15, 2006
Last Update Posted : September 15, 2006
Sponsor:
Information provided by:
University of Regensburg

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
It was the aim of the present study to prospectively compare the functional and morphological outcome of idiopathic epiretinal membrane surgery with and without the assistance of Indocyanine green (ICG). The main outcome measure was improvement of best-corrected visual acuity (BCVA). This was treated as an open question and we had no hypothesis which of the two therapies was superior.

Condition or disease Intervention/treatment Phase
Idiopathic Epiretinal Membrane, Cataract Drug: Surgery with and without the aid of Indocyanine Green (ICG) Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The main outcome measure was improvement of best-corrected visual acuity (BCVA).

Secondary Outcome Measures :
  1. Other outcome measures included postoperative BCVA, status of Amsler grid test, reduction of macular retinal thickness, residual or recurrent macular epiretinal membrane

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with IEM and cataract or posterior chamber intraocular lens pseudophakia complaining of loss of visual acuity and metamorphopsia during the past six months.

Exclusion Criteria:

  • Other retinal disease, non-idiopathic epiretinal membrane, glaucoma or history of retinal detachment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376857


Locations
Layout table for location information
Germany
Dept. of Ophthalmology, University of Regensburg
Regensburg, Germany, 93042
Sponsors and Collaborators
University of Regensburg
Investigators
Layout table for investigator information
Principal Investigator: Jost Hillenkamp, MD Dept. of Ophthalmology, University of Regensburg
Principal Investigator: Parykshit Saikia, MD Dept. of Ophthalmology, University of Regensburg
Study Chair: Helmut G Sachs, MD Dept. of Ophthalmology, University of Regensburg
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00376857    
Other Study ID Numbers: 03123
First Posted: September 15, 2006    Key Record Dates
Last Update Posted: September 15, 2006
Last Verified: September 2006
Keywords provided by University of Regensburg:
Indocyanine green, toxicity, epiretinal membrane, visual field defect
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Epiretinal Membrane
Lens Diseases
Eye Diseases
Retinal Diseases